TST106

Claudin 18.2-X

Target:: Claudin 18.2-X

Indication:: G/ GEJC and other Solid Tumors

Project Status:: Preclinical

TST106 is a humanized bispecific antibody-based drug conjugate (ADC) targeting CLDN18.2 and an undisclosed tumor antigen expressed in multiple tumor types. The bispecific antibody is designed to force the antibody to only bind to dual expressing tumor cells but not to CLDN18.2 expressing normal gastric epithelial cells and thus improve safety and efficacy in the targeting population.